2015 - Cancer Currents Blog
-
Patients with advanced cancer may benefit from having discussions about their prognoses with their physicians.
-
A team of NCI researchers has reported that several types of gastrointestinal cancer have tumor-specific mutations that can be recognized by the immune system, thereby offering a new therapeutic opportunity for patients with these tumors.
-
A new approach to disrupting genes that promote the development and spread of tumors may hold promise for treating an aggressive and difficult-to-treat type of breast cancer.
-
A number of NCI programs and networks are the foundation of the National Cancer Program and play a critical role in promoting progress.
-
Women in a clinical trial who became pregnant after vaccination with a bivalent human papillomavirus (HPV) vaccine did not have an increased risk of miscarriage.
-
The FDA has approved a single drug that combines trifluridine and tipiracil to treat patients with metastatic colorectal cancer whose disease progressed after standard treatment.
-
Acting NCI Director Doug Lowy, M.D., discusses the critical contribution of basic science in fostering progress against cancer.
-
The Partnership for Public Service presented the 2015 People’s Choice Award to the government staff and researchers who have worked on The Cancer Genome Atlas.
-
The Partnership for Public Service has awarded Steven A. Rosenberg, M.D., of NCI's Center for Cancer Research, with its highest 2015 Samuel J. Heyman Service to America Medal, or Sammie.
-
The persistence of genetic mutations in some patients with acute myeloid leukemia may allow physicians to better classify their risk of recurrence.